Sernova Biotherapeutics Inc
SVA.TO
TSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.21% | -18.78% | -15.99% | -9.55% | -13.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.89% | -54.10% | -56.60% | -51.44% | -38.03% |
| Operating Income | 53.89% | 54.10% | 56.60% | 51.44% | 38.03% |
| Income Before Tax | 56.14% | 52.68% | 53.89% | 48.47% | 32.18% |
| Income Tax Expenses | -635.42% | 21.57% | -- | -- | -- |
| Earnings from Continuing Operations | 56.41% | 52.66% | 53.71% | 48.35% | 32.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.41% | 52.66% | 53.71% | 48.35% | 32.15% |
| EBIT | 53.89% | 54.10% | 56.60% | 51.44% | 38.03% |
| EBITDA | 54.07% | 54.30% | 56.71% | 51.68% | 38.27% |
| EPS Basic | 59.09% | 56.06% | 56.83% | 50.55% | 33.60% |
| Normalized Basic EPS | 58.50% | 55.88% | 56.85% | 50.71% | 33.76% |
| EPS Diluted | 59.09% | 56.06% | 56.83% | 50.55% | 33.60% |
| Normalized Diluted EPS | 58.50% | 55.88% | 56.85% | 50.71% | 33.76% |
| Average Basic Shares Outstanding | 5.60% | 6.95% | 7.27% | 5.24% | 3.18% |
| Average Diluted Shares Outstanding | 5.60% | 6.95% | 7.27% | 5.24% | 3.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |